Nakanishi (7716): A Stock Split Doesn't Fix a Pricey Valuation

On August 7, 2026, Nakanishi Inc. delivered two headlines at once. The company reported H1 earnings of ¥8.144 billion — up year-over-year — and simultaneously announced a 2-for-1 stock split effective October 1. The stock has rallied roughly 64% year-to-date, now sitting around ¥3,245. In the Tokyo market, where a stock split is often read as management's signal that the share price is going higher, the message feels unmistakably bullish.

The only problem is the math doesn't quite support a breakout story right now.

Nakanishi trades at approximately 22 times forward 2026 earnings, compressing to about 19.6x on 2027 estimates. That is not a GARP valuation for a company in the dental handpiece business — a mature global market growing at roughly 4.65% annually. The stock split changes nothing about the economics. It doubles the share count from 92.2 million to 184.4 million, halves the nominal price, and does zero to alter market capitalization. It is a mechanical event, not a catalyst.

So what is the real disconnect here? The market appears to be treating Nakanishi as a growth story at a premium multiple, when the evidence points more toward a mature cash generator that just cleared a one-time overhang. Let me walk through the three pieces of the puzzle.

The Impairment Cleared. The Margins Are Back — But They're Not a Surprise.

In fiscal 2025 (year ending December 2025), Nakanishi swung to a net loss of ¥2 billion on ¥81 billion in revenue. The headline driver was a ¥14 billion impairment on its DCI International business — the US dental chair manufacturer Nakanishi fully acquired in 2023. That one-time charge is now in the rear-view mirror. H1 2026 earnings of ¥8.144 billion, plus a strong Q1 where net income jumped 803.9% year-over-year, confirm the underlying business is profitable again.

But here's what the numbers already show: operating profit for FY2025 was ¥14 billion, or roughly a 17% operating margin. Historically, Nakanishi's core dental handpiece business has delivered ordinary profit margins above 30%, driven by vertical integration — the company manufactures 80–85% of parts in-house at its A1 factory in Kanuma, Tochigi. The DCI dental-chair business is lower-margin, and it is pulling the blended result down. If you separate the core from the acquisition, the math is old news. The impairment was temporary, and the core is still a high-margin manufacturer. That is good, but it is not a re-rating catalyst.

The M&A Gamble: Growth or Drag?

Nakanishi's NV2030 mid-term plan, announced in August 2025, puts M&A at the center of its strategy. Since 2020, the company has acquired DCI International, Alfred Jäger (Germany, high-frequency spindles), Guilin REFINE (China), and most recently Acra Cut and Intech (US, surgical instruments, announced March 2026). Headcount has roughly doubled from 1,184 to 2,204.

The open question is whether Nakanishi can impose its 30%+ margins on acquired businesses. The DCI impairment suggests the answer is not automatic. Revenue grew — from $310 million in FY2020 to $542 million in FY2025 — but operating profit stayed flat around $94 million. That is revenue growth without operating leverage, which means the acquisitions are not yet contributing proportionally to profitability. The market is pricing a growth multiple on a business that has demonstrated top-line expansion but has yet to prove it can integrate acquired operations into its historically pristine margin structure. Until the Acra Cut and Intech deals show accretive results, the M&A thesis remains a bet, not evidence.

Management Signals: Mixed Bag

The stock split itself is a neutral-to-positive signal. Management typically splits shares when the nominal price gets high enough to reduce retail accessibility. At ¥3,245 per share, that's not out of reach for serious Japanese investors, but splitting makes the stock feel more liquid. Combined with H1 earnings, management is telling the market it expects the stock to trade higher.

But look at what they did not do. In February 2026, the Board authorized a share buyback of up to 1.5 million shares (1.81% of outstanding) for a maximum of ¥2.5 billion. As of May 2026, zero shares had been acquired. Zero. Management was given the green light and the budget to buy back stock and chose not to. When a company authorizes a buyback and then sits idle, the most natural reading is that management considers the stock fairly valued or better. That does not align with a breakout thesis.

Peer Context and the Forward Multiple

The dental handpiece market is led by KaVo Dental (part of Envista Holdings) and Dentsply Sirona in the US and Europe. Nakanishi historically held roughly 15% of the global market and 60–80% share in Southeast Asia. The competitive landscape is stable — no disruption, no pricing wars, no secular tailwind. The electric handpiece transition is gradual. Market reports project global revenue reaching $2.33 billion by 2035, growing at a mid-single-digit CAGR. That is a mature, slowly compounding industry.

At 22x forward earnings, Nakanishi is priced as if it is growing faster than the market it operates in. A mature medical device maker in a ~5% growth industry should trade at a multiple closer to 15–17x earnings unless there is a proven margin expansion story or a new high-growth segment that is already generating revenue. The surgical instruments push via Acra Cut and Intech sounds promising in principle, but it is a new business line with no track record at Nakanishi. Forward estimates for FY2026 project ¥91.96 billion in sales and ¥12.52 billion in net income. The P/E of 22x assumes all those numbers materialize — no more M&A impairment hits, no FX shocks, smooth integration.

The Verdict: Fair Value at Best, No Edge Here

The false narrative around Nakanishi is that it is a beaten-down recovery story trading at a discount. It is not. The stock has rallied 64% year-to-date. It trades at a premium multiple on forward earnings. The one-time impairment overhang is already behind the business. The real story — whether M&A can drive margin expansion and whether the surgical instruments business can scale — is simply not yet proven.

At 22x forward earnings in a ~5% growth market with unexecuted buybacks, this is not a GARP setup. It is fair value at best. The stock split is cosmetic. The catalyst the market needs to justify this multiple — accretive M&A integration, surgical business ramp, margin re-expansion to 30%+ — has not happened yet.

For investors, the setup here is watch, not buy. I would need to see two things before getting long: first, evidence that Acra Cut and Intech are contributing to blended margin expansion, and second, a pullback to the high-teen P/E range where the multiple matches the growth rate. Until then, the math and the narrative are aligned — and when they are aligned, there is no edge.

A break condition that would change my view: if Nakanishi executes the ¥2.5 billion buyback authorization at current prices, that would be a clear management-confidence signal at a valuation I could respect. Alternatively, if the stock pulls back below ¥2,500 — roughly 17x forward earnings — the valuation would carry the thesis. But as of today, at ¥3,245, this is not a misunderstood stock. The market is actually getting the price about right.